Kenan Turnacioglu is a General Partner at Catalio Capital Management, LP, where he also serves on the Public Equities and Nexus Investment Committees.
He is also the Chairman of the Board of PaigeAI, a machine learning pathology company, and ManaT Bio, an immune-oncology company.
Prior to joining Catalio, Kenan was a Co-Founder of PointState Capital, LP, a long short equity hedge fund, where he managed the portfolios and investment teams in Healthcare and Consumer sectors, before departing in 2018. From 2001 to 2010, he was a Managing Director and Portfolio Manager at Duquesne Capital Management, LLC, managing Healthcare investments. He also served on the Boards of StemCentrx, Agensys and NYU Langone Cancer Center. From 1998 to 2000, he was a Biotechnology Analyst at Credit Suisse.
Kenan earned a B.A. from Rutgers University and a Ph.D. from the University of Pennsylvania, before becoming a Post-Doctoral Fellow at Johns Hopkins University.